ArticleLife (Basel, Switzerland)2021
The Core of Gut Life:
Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.Journal of neurology · 2024Pooled it
- Sexual dimorphism in the colonic microbiome and host's transcriptomics profiles of a murine model of multiple sclerosis.Clinical immunology communications · 2026Article
- Immunotherapy-Mediated Modulation of the Gut Microbiota in Multiple Sclerosis: The Effects of High-Efficacy (Cladribine) and Moderate-Efficacy (Interferon Beta-1a) Treatments.International journal of molecular sciences · 2026Article
- Gut Microbiome Signatures in Multiple Sclerosis: A Case-Control Study with Machine Learning and Global Data Integration.Biomedicines · 2025Article
- Landscapes of gut microbiome and blood metabolomic signatures in relapsing remitting multiple sclerosis.Science China. Life sciences · 2025Article
- Gut microbiota in multiple sclerosis and animal models.The FEBS journal · 2025Review
- Distinct Ocular Surface Microbiome in Keratoconus Patients Correlate With Local Immune Dysregulation.Investigative ophthalmology & visual science · 2025Article
- Potential Applications of Blautia wexlerae in the Regulation of Host Metabolism.Probiotics and antimicrobial proteins · 2024Review
- Identification of commensal gut microbiota signatures as predictors of clinical severity and disease progression in multiple sclerosis.Scientific reports · 2024Article
- Article
- Homocysteine as a Predictor Tool in Multiple Sclerosis.Discoveries (Craiova, Romania)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The multiple sclerosis (MS) incidence rate has been increasing in Russia, but the information about the gut bacteriobiome in the MS-afflicted patients is scarce. Using the Illumina MiSeq sequencing of 16S rRNA gene amplicons, we aimed to analyze the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.